Halberd Corporation's VITA-SHIELD-MAX(TM) Immunity Support Product Shipped

Rhea-AI Summary

Halberd Corporation (OTC PINK:HALB) has announced the shipment of its Vita-Shield-Max^TM nutraceutical product, coinciding with a rise in Covid-19 cases due to the Delta Variant. CEO William A. Hartman indicated that sales will commence shortly, with purchasing details to follow. The company previously released a 120-page compilation of medical articles supporting Vita-Shield-Max. Halberd holds exclusive rights to several patents for treatments related to COVID-19, acknowledging ongoing risks and uncertainties linked to the pandemic and its effect on operations.

Positive

• Shipment of Vita-Shield-Max occurs at a critical time with rising Covid-19 cases.
• Halberd is preparing to sell its product soon, suggesting potential revenue generation.
• Company holds exclusive rights to several patents for COVID-19 treatments.

Negative

• Uncertainty in the impact of COVID-19 on operations and financial performance.
• Potential risks from SEC scrutiny on public companies involved in COVID-19 initiatives.

JACKSON CENTER, PA / ACCESSWIRE / August 9, 2021 / Halberd Corporation (OTC PINK:HALB) reports Vita-Shield-Max^TM, has been shipped! With Covid-19 cases back on the rise fueled by the Delta Variant, this "Immunity Support Nutraceutical Product" is arriving at the right time.

William A. Hartman, Halberd's Chairman, President & CEO, stated, "We will shortly begin selling Vita-Shield-Max^TM and will be releasing details on purchasing our product in the near future, once we have the product in inventory."

Halberd Corporation released a 120-page compilation of medical articles in support of its VITA-SHIELD-MAX^TM Nutraceutical product earlier.

To get the latest news on Halberd's exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com;
support@halberdcorporation.com
http://www.halberdcorporation.com
Twitter:@HalberdC

About Halberd Corporation.

Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It holds the exclusive worldwide rights to several patent- and PCT-pending extracorporeal treatments for COVID-19 and other medical maladies: Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.

Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives -

On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.

The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.

The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.

SOURCE: Halberd Corporation

View source version on accesswire.com:
https://www.accesswire.com/658881/Halberd-Corporations-VITA-SHIELD-MAXTM-Immunity-Support-Product-Shipped

FAQ

What is Vita-Shield-Max from Halberd Corporation?

Vita-Shield-Max is an immunity support nutraceutical product shipped by Halberd Corporation.

When will Halberd Corporation start selling Vita-Shield-Max?

Halberd Corporation plans to start selling Vita-Shield-Max shortly after it builds inventory.

What is the stock symbol for Halberd Corporation?

The stock symbol for Halberd Corporation is HALB.

What patents does Halberd Corporation hold related to COVID-19?

Halberd Corporation holds exclusive worldwide rights to several patents and PCT-pending treatments for COVID-19.

What are the risks mentioned by Halberd Corporation?

Halberd Corporation acknowledges risks related to the COVID-19 pandemic and potential SEC scrutiny affecting its operations.